NAMS MENOPAUSE CERTIFICATION A MASTERY 150 CORRECT VERIFIED ANSWERS WITH DETAILED RATIONALES INSTANT DOWNLOAD

NAMS MENOPAUSE CERTIFICATION A
MASTERY 150 CORRECT VERIFIED
ANSWERS WITH DETAILED RATIONALES
INSTANT DOWNLOAD


NAMS MENOPAUSE CERTIFICATION EXAM
Comprehensive Study Guide with Detailed Rationales
Question 1: A 53-year-old woman presents to your clinic reporting that
her menstrual cycles have become increasingly unpredictable over the
past 14 months, with intervals ranging from 21 to 58 days; she is
experiencing moderate hot flashes, occasional sleep disruption, and mild
vaginal dryness. Her last menstrual period was 11 months ago, and she
has no personal history of thromboembolism, breast cancer, or liver
disease. According to the STRAW+10 staging system and NAMS clinical
guidelines, how should this patient’s reproductive stage be classified, and
what is the most appropriate initial management approach for her
vasomotor symptoms? A) Postmenopause; initiate continuous-combined
oral estrogen-progestogen therapy immediately. B) Late reproductive
stage; recommend lifestyle modifications only, as hormone therapy is
not indicated until 12 months of amenorrhea. C) Late menopausal
transition; offer systemic menopausal hormone therapy (MHT) with
appropriate endometrial protection, as she is within the therapeutic
window and has no contraindications. D) Early menopausal transition;
prescribe high-dose transdermal testosterone to address fatigue and low
libido. Correct Answer: C - Late menopausal transition; offer
systemic menopausal hormone therapy (MHT) with
appropriate endometrial protection, as she is within the
therapeutic window and has no contraindications. The
STRAW+10 system defines the late menopausal transition as cycles that
are ≥60 days apart or skipped entirely. Since she has had 11 months of
amenorrhea but not yet 12, she remains in the late transition. NAMS
guidelines recommend systemic MHT as the most effective treatment
for moderate-to-severe vasomotor symptoms in healthy women under
60 or within 10 years of menopause onset. Because she has an intact

,uterus, endometrial protection with a progestogen or tissue-selective
estrogen complex is mandatory.


Question 2: A 51-year-old woman with severe, treatment-refractory
vasomotor symptoms is being evaluated for non-hormonal
pharmacological options; she has a strong family history of venous
thromboembolism and prefers to avoid systemic estrogen. The clinician
prescribes a novel, FDA-approved medication that specifically targets the
neurokinin 3 (NK3) receptor in the hypothalamus to normalize the
narrowed thermoneutral zone associated with estrogen depletion. Which
medication has been prescribed, and what is the primary laboratory
monitoring requirement during therapy? A) Venlafaxine; monitor serum
sodium for hyponatremia. B) Gabapentin; monitor renal function and
adjust dose for creatinine clearance. C) Fezolinetant; monitor liver
function tests (ALT, AST, bilirubin) at baseline, 3, 6, and 9 months due
to hepatotoxicity risk. D) Clonidine; monitor blood pressure and heart
rate for rebound hypertension. Correct Answer: C - Fezolinetant;
monitor liver function tests (ALT, AST, bilirubin) at baseline,
3, 6, and 9 months due to hepatotoxicity risk. Fezolinetant is a
non-hormonal, NK3 receptor antagonist FDA-approved for moderate-
to-severe vasomotor symptoms. It works by inhibiting KNDy neuron
overactivity in the hypothalamus. Due to post-marketing reports of
elevated transaminases and rare cases of drug-induced liver injury,
NAMS and the FDA mandate baseline and periodic hepatic monitoring
during treatment. It does not require hormonal monitoring or renal
adjustments like gabapentin.


Question 3: A 58-year-old woman presents with persistent
dyspareunia, vaginal burning, and recurrent urinary tract infections
despite regular use of over-the-counter vaginal moisturizers; pelvic
examination reveals pale, thin vaginal epithelium with loss of rugae,
petechiae, and a vaginal pH of 5.8. She has a remote history of stage I
estrogen receptor-positive breast cancer treated with lumpectomy and
radiation 8 years ago, and she is not on endocrine therapy. According to
NAMS and ASCO guidelines, what is the safest and most effective next
step in management? A) Prescribe systemic oral conjugated equine
estrogens with micronized progesterone. B) Initiate low-dose vaginal
estrogen therapy after shared decision-making, recognizing that

,systemic absorption is minimal and current data do not show increased
breast cancer recurrence risk. C) Recommend permanent cessation of all
vaginal treatments due to absolute contraindication with breast cancer
history. D) Prescribe oral ospemifene, as it is the only FDA-approved
option for breast cancer survivors with GSM. Correct Answer: B -
Initiate low-dose vaginal estrogen therapy after shared
decision-making, recognizing that systemic absorption is
minimal and current data do not show increased breast cancer
recurrence risk. Low-dose vaginal estrogen preparations deliver
localized hormone therapy with minimal systemic absorption, keeping
serum estradiol within postmenopausal ranges. NAMS and ASCO state
that while absolute contraindications exist for systemic estrogen in
breast cancer survivors, low-dose vaginal estrogen may be considered
after non-hormonal therapies fail and through shared decision-making,
as observational data have not demonstrated increased recurrence
risk. Ospemifene is a systemic SERM and is not recommended for
women with a history of ER+ breast cancer.


Question 4: A 45-year-old woman presents with amenorrhea for 9
months, hot flashes, night sweats, and vaginal dryness; laboratory
testing reveals an FSH of 72 mIU/mL and estradiol of 12 pg/mL on two
separate occasions 4 weeks apart. She has no history of chemotherapy,
radiation, pelvic surgery, or autoimmune disease. According to NAMS
and international consensus guidelines, what is the correct diagnosis and
recommended duration of hormone therapy? A) Normal perimenopause;
no treatment needed as cycles may resume spontaneously. B) Premature
Ovarian Insufficiency (POI); initiate systemic hormone therapy and
continue at least until the average age of natural menopause (~51 years)
to protect bone, cardiovascular, and cognitive health. C) Functional
hypothalamic amenorrhea; treat with weight restoration and stress
reduction alone. D) Early menopause; prescribe hormone therapy for 2
years only to avoid long-term risks. Correct Answer: B - Premature
Ovarian Insufficiency (POI); initiate systemic hormone
therapy and continue at least until the average age of natural
menopause (~51 years) to protect bone, cardiovascular, and
cognitive health. POI is defined as hypergonadotropic hypogonadism
before age 40. Women with POI experience prolonged estrogen
deficiency, significantly increasing risks for osteoporosis,
cardiovascular disease, and cognitive decline. NAMS strongly

, recommends systemic hormone replacement (or combined oral
contraceptives if contraception is desired) until at least age 50-51 to
mitigate these long-term health risks, provided no contraindications
exist.


Question 5: A 56-year-old woman with a history of severe
hypertriglyceridemia (fasting triglycerides 420 mg/dL) and well-
controlled hypertension presents with debilitating hot flashes and night
sweats. She has an intact uterus and requests hormone therapy.
According to NAMS guidelines regarding the route of estrogen
administration, which regimen is safest and most appropriate for her
metabolic profile? A) Oral conjugated equine estrogens with
medroxyprogesterone acetate. B) Transdermal estradiol patch with oral
micronized progesterone. C) Oral estradiol with drospirenone. D)
Subcutaneous estrogen pellets with a levonorgestrel IUD. Correct
Answer: B - Transdermal estradiol patch with oral micronized
progesterone. Oral estrogen undergoes first-pass hepatic
metabolism, stimulating VLDL and triglyceride synthesis, which can
exacerbate hypertriglyceridemia and increase pancreatitis risk.
Transdermal estrogen bypasses the liver, resulting in stable systemic
estradiol levels without hepatic lipid stimulation. NAMS recommends
transdermal estrogen as the preferred route for women with fasting
triglycerides >400 mg/dL, along with endometrial protection
(micronized progesterone or LNG-IUD).


Question 6: A 62-year-old woman, 8 years postmenopausal, presents
for routine health maintenance; she has never used hormone therapy
and asks if starting estrogen now will protect her from future heart
attacks. According to the WHI data and the "timing hypothesis," what is
the most accurate counseling regarding cardiovascular disease
prevention and MHT? A) MHT is FDA-approved and recommended for
primary cardiovascular prevention in all postmenopausal women. B)
Initiating MHT after age 60 or more than 10 years from menopause
onset does not provide cardiovascular benefit and may increase the risk
of coronary events and stroke. C) Transdermal estrogen is proven to
reverse atherosclerotic plaque in women over 65. D) MHT should be
combined with daily aspirin to maximize cardioprotection in older
women. Correct Answer: B - Initiating MHT after age 60 or